PMID: 9434825Jan 22, 1998Paper

Emergence of secondary acute leukemia in a patient treated for osteosarcoma: implications of germline TP53 mutations

Medical and Pediatric Oncology
C PanizoE Rocha

Abstract

Secondary leukemia and myelodysplastic syndromes have been reported in patients following treatment for a wide range of neoplastic disorders. However second malignancies after chemotherapy and/or irradiation for osteosarcoma are unusual. We report the case of a 15-year-old girl who developed a myelodysplastic syndrome with evolution to acute nonlymphocytic leukemia after treatment for osteosarcoma. Therapy-related acute leukemia karyotype findings such as abnormalities of chromosomes 5, 7, and 17 were found in the cytogenetic analysis. Moreover, using denaturing gradient gel electrophoresis and DNA sequencing, we detected the presence of a double germline mutation in exon 7 of the TP53 gene. This observation supports the possibility of a causal relationship between germline TP53 mutations and the development of secondary leukemia and myelodysplasia.

References

Jan 1, 1992·Medical and Pediatric Oncology·C KaplinskyR Zaizov
Oct 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·A L BørresenS H Friend
Aug 18, 1990·Lancet·C H PuiC B Pratt
Aug 1, 1987·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P FenauxP Lepelley
Apr 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A T MeadowsS G Sallan
Jan 1, 1986·Medical and Pediatric Oncology·M A Knowling, V E Basco
Apr 1, 1988·Cancer Genetics and Cytogenetics·S V DaviesS M Bowser-Riley
Jan 1, 1988·Medical and Pediatric Oncology·J M DewarR A Joske
Sep 1, 1987·British Journal of Cancer·J E KingstonL M Kinnier Wilson
Dec 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H M KantarjianE J Freireich
Mar 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·S G Fischer, L S Lerman
May 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J F McIntyreJ Miser
Aug 1, 1993·International Journal of Radiation Oncology, Biology, Physics·S S Donaldson
Oct 28, 1993·The New England Journal of Medicine·C C Harris, M Hollstein

❮ Previous
Next ❯

Citations

Oct 28, 1998·Proceedings of the National Academy of Sciences of the United States of America·C A FelixT R Rebbeck
Sep 13, 2001·Proceedings of the National Academy of Sciences of the United States of America·J M AllanG J Morgan
Apr 21, 2011·JAMA : the Journal of the American Medical Association·Daniel C LinkElaine R Mardis
Jan 24, 2007·Langenbeck's Archives of Surgery·A DaigelerC Kuhnen
Feb 28, 2001·British Journal of Haematology·L PaganaUNKNOWN Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto
Oct 18, 2001·Clinical Orthopaedics and Related Research·A KawaiH Inoue
Jun 26, 2004·Journal of Pediatric Hematology/oncology·M Carmen EscuderoLuis Madero
May 8, 2001·Medical and Pediatric Oncology·C A Felix
May 22, 2003·Journal of Pediatric Hematology/oncology·Ana Patiño-GarcíaLuis Sierrasesúmaga Ariznabarreta
Mar 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marie-Cécile Le DeleyUNKNOWN Société Française d'Oncologie Pédiatrique

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.